News

Owens & Minor Names Chief Operating Officer

Owens & Minor, a global healthcare solutions company providing essential products, services and technology solutions that support care delivery in leading hospitals, health systems and research centers around the world, today announced Marc Rottink as Chief Operating Officer (COO) of Owens & Minor, effective immediately.

Rottink brings almost three decades of experience in leading global, multi-site healthcare supply chain operations, including strategic transformation, oversight and management of global inventory assets and distribution operations, integrated business planning, systems implementation, and cross-functional operations alignment. Most recently, Marc served as Senior Vice President of Global Supply Chain and Customer Care for Smith + Nephew. Under his leadership, Smith + Nephew saw significant improvement in its manufacturing operations, as well as sales, inventory, and operational planning (SIOP), greatly enhancing customer fulfillment levels. Prior to Smith + Nephew, Marc served as Vice President of Global Supply Chain for Medtronic’s Restorative Therapies Group.

“In logistics, operational excellence is important, but in healthcare logistics, it’s critical,” said Christian Cook, chairman and interim CEO, Owens & Minor, and managing director at Platinum Equity. “We’re making significant investments in our operations through automation and we’re confident that Marc’s impressive history of successfully leading global operational transformation will be a pivotal asset as Owens & Minor continues to improve the customer experience.”

“Throughout my career, I’ve had great passion for developing and implementing large-scale strategies that help supply chains and product manufacturing operate more efficiently and more responsively,” said Marc Rottink, Chief Operating Officer (COO), Owens & Minor. “I’m more than thrilled to join Owens & Minor and excited for the opportunity to innovate and improve the backbone of our strength—our 140+ years of operational expertise—and take it to the next level.”

On December 31, 2025, Owens & Minor announced a new chapter in its long and storied history: the medical distribution, products and technology services business, formerly referred to as Products & Healthcare Services (P&HS), is now part of the Platinum Equity portfolio. The company continues to operate as a private standalone company under the Owens & Minor name, carrying on the legacy of excellence and service the company has long been known for.

Read more here.

Recent News

09/03/2026

Seppic announces the appointment of Virginie Cavalli as Chief Executive Officer

A subsidiary of Air Liquide Healthcare, Seppic designs, manufactures, and distributes a wide range of specialty ingredients used in cosmetics, nutraceuticals, pharmaceuticals, veterinary products, and industrial applications. Nearly 900 employees support customers in 100 countries through the company’s subsidiaries and distributor network. With a degree from EMLyon school in business and financial strategy, Virginie Cavalli

09/01/2026

Andre Marshall to join National Science Foundation; Aurali Dade named Interim Vice President for Research, Innovation, and Economic Impact

Since joining George Mason in 2021, Marshall has played a pivotal role in advancing the university’s research enterprise and entrepreneurial ecosystem and strengthening the university’s reputation as a leading public R1 institution, including launching the Grand Challenge Initiative and empowering institute-driven initiatives like Nexus234 and the Virginia Climate Center. During Marshall’s tenure, George Mason expanded research activity and strategic partnerships,

08/25/2026

United Therapeutics Corporation Announces FDA Filing Acceptance of New Drug Application for Ralinepag to Treat Pulmonary Arterial Hypertension

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the FDA has accepted the New Drug Application (NDA) for ralinepag to treat PAH. The FDA has set a Prescription Drug User Fee Act target action date of June 24, 2027. Ralinepag has not been approved for use in any indication by the